Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...
SurvivorNet on MSN2mon
For Advanced Breast Cancer With a PIK3CA Mutation, A New Three-Drug Combination Doubles Progression-Free Survival, According to New StudyPalbociclib (brand name Ibrance) was the first CDK 4/6 inhibitor approved by the FDA to treat breast cancer. In combination, ...
Unlocking the potential of next-generation breast cancer treatments “The emergence of CDK inhibitors for the treatment of breast cancer has been pivotal in improving the standard of care for ...
“Although breast-cancer treatments continue to get better ... risk of recurrence include treatments such as immunotherapy and ...
Recent work has discovered the role of the cyclin-dependent kinase (CDK)-binding protein Cks1 in ... replication and is aberrantly enhanced in cancer. Surprisingly, new work indicates that this ...
Professor Eugenia Broude CDK8/19 Mediator Kinase CDK8/19 Mediator kinase in multiple cancers Expression of CDK8/19 Media ...
Investigators from the University of Michigan and affiliated organizations published data from a study that aimed to investigate the role of cyclin-dependent kinase 12 (CDK12) in prostate cancer (PCa) ...
CDK Global reportedly paid $25 million to cybercriminals after a mid-June ransomware attack disrupted business for thousands of car dealerships. According to a report from CNN citing multiple ...
A personalised, treatment plan for patients with breast cancer is the first digital health ... Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback